Analysts fell to the sidelines weighing in on Acorda Therapeutics (NASDAQ:ACOR) and Cutera (NASDAQ:CUTR) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks.
Acorda Therapeutics (ACOR)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Acorda Therapeutics, with a price target of $19. The company’s shares closed yesterday at $18.66, close to its 52-week low of $15.60.
According to TipRanks.com, Matteis is a 5-star analyst with an average return of 26.7% and a 57.7% success rate. Matteis covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Acorda Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $24.71, a 32.4% upside from current levels. In a report issued on September 23, Oppenheimer also reiterated a Hold rating on the stock with a $18 price target.
.
See today’s analyst top recommended stocks >>
Cutera (CUTR)
In a report released today, Jonathan Block from Stifel Nicolaus maintained a Hold rating on Cutera, with a price target of $29. The company’s shares closed yesterday at $29.78, close to its 52-week low of $29.15.
According to TipRanks.com, Block is a 5-star analyst with an average return of 21.2% and a 71.7% success rate. Block covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Idexx Laboratories, and Align Tech.
Currently, the analyst consensus on Cutera is a Moderate Buy with an average price target of $40, a 34.3% upside from current levels. In a report released today, Maxim Group also maintained a Hold rating on the stock.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
